Xeris to Participate in Upcoming Investor Conferences
Xeris Biopharma Holdings (Nasdaq: XERS) has announced its participation in three major upcoming healthcare investor conferences in early 2025. The company will participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, featuring a fireside chat at 1:20 pm ET. Subsequently, Xeris will attend the Leerink Global Healthcare Conference in Miami on March 10, with a fireside chat scheduled for 8:40 am ET, followed by the Barclays 27th Annual Global Healthcare Conference in Miami on March 11 for 1x1 meetings only.
The growth-oriented biopharmaceutical company, focused on developing and commercializing innovative therapeutic products, will have its senior management team available for one-on-one meetings at all three events. Interested parties can access webcast information for the fireside chats through Xeris' investor relations website.
Xeris Biopharma Holdings (Nasdaq: XERS) ha annunciato la sua partecipazione a tre importanti conferenze per investitori nel settore sanitario all'inizio del 2025. L'azienda parteciperà alla 35a Conferenza Annuale di Oppenheimer sulle Scienze della Vita e Salute il 12 febbraio, con un incontro informale programmato alle 13:20 ET. Successivamente, Xeris parteciperà alla Conferenza Globale sulla Sanità di Leerink a Miami il 10 marzo, con un incontro informale previsto per le 8:40 ET, seguita dalla 27a Conferenza Globale Annuale sulla Sanità di Barclays a Miami l'11 marzo, dedicata esclusivamente agli incontri one-to-one.
L'azienda biofarmaceutica orientata alla crescita, focalizzata sulla sviluppo e commercializzazione di prodotti terapeutici innovativi, avrà a disposizione il proprio team di gestione senior per incontri individuali in tutti e tre gli eventi. Le parti interessate possono accedere alle informazioni sul webcast per gli incontri informali tramite il sito web delle relazioni con gli investitori di Xeris.
Xeris Biopharma Holdings (Nasdaq: XERS) ha anunciado su participación en tres importantes conferencias para inversores del sector salud a principios de 2025. La empresa participará en la 35ª Conferencia Anual de Ciencias de la Vida y Salud de Oppenheimer el 12 de febrero, con un chat informal programado para la 1:20 p.m. ET. Posteriormente, Xeris asistirá a la Conferencia Global de Salud de Leerink en Miami el 10 de marzo, con un chat informal previsto para las 8:40 a.m. ET, seguido de la 27ª Conferencia Global Anual de Salud de Barclays en Miami el 11 de marzo, que será solo para reuniones uno a uno.
La empresa biofarmacéutica orientada al crecimiento, enfocada en desarrollar y comercializar productos terapéuticos innovadores, tendrá a su equipo de alta dirección disponible para reuniones individuales en los tres eventos. Las partes interesadas pueden acceder a la información de la transmisión web para los chats informales a través del sitio web de relaciones con inversores de Xeris.
Xeris Biopharma Holdings (Nasdaq: XERS)는 2025년 초에 있을 3개의 주요 헬스케어 투자자 회의에 참가할 예정이라고 발표했습니다. 이 회사는 2월 12일에 열리는 오펜하이머 제35회 연례 생명 과학 헬스케어 회의에 참가하며, 오후 1시 20분(ET)에 진행되는 파이어사이드 채팅이 예정되어 있습니다. 그 후, Xeris는 3월 10일 마이애미에서 열리는 리어링크 글로벌 헬스케어 회의에 참석하고, 오전 8시 40분(ET)에 예정된 파이어사이드 채팅에 참석한 후, 3월 11일 마이애미에서 열리는 바클레이스 제27회 연례 글로벌 헬스케어 회의에 대해서는 1x1 미팅만 진행할 예정입니다.
성장 지향적인 이 생명공학 회사는 혁신적인 치료 제품 개발 및 상용화에 중점을 두고 있으며, 모든 회의에서 1대1 미팅을 위해 고위 경영진 팀을 배치할 예정입니다. 관심 있는 당사자는 Xeris의 투자자 관계 웹사이트를 통해 파이어사이드 채팅에 대한 웹캐스트 정보를 확인할 수 있습니다.
Xeris Biopharma Holdings (Nasdaq: XERS) a annoncé sa participation à trois grandes conférences à venir pour investisseurs dans le secteur de la santé début 2025. L'entreprise participera à la 35e Conférence Annuelle Oppenheimer sur les Sciences de la Vie et la Santé le 12 février, avec un entretien informel prévu à 13h20 ET. Ensuite, Xeris assistera à la Conférence Mondiale sur la Santé de Leerink à Miami le 10 mars, avec un entretien informel programmé à 8h40 ET, suivi par la 27e Conférence Annuelle Mondiale sur la Santé de Barclays à Miami le 11 mars, uniquement pour des réunions individuelles.
L'entreprise biopharmaceutique axée sur la croissance, spécialisée dans le développement et la commercialisation de produits thérapeutiques innovants, aura son équipe de direction senior disponible pour des réunions individuelles lors des trois événements. Les parties intéressées peuvent accéder aux informations relatives aux webcasts pour les entretiens informels via le site web des relations avec les investisseurs de Xeris.
Xeris Biopharma Holdings (Nasdaq: XERS) hat seine Teilnahme an drei großen bevorstehenden Investorenkonferenzen im Gesundheitswesen Anfang 2025 bekannt gegeben. Das Unternehmen wird am 12. Februar an der 35. Jahreskonferenz für Lebenswissenschaften und Gesundheitswesen von Oppenheimer teilnehmen, mit einem informellen Gespräch um 13:20 Uhr ET. Anschließend wird Xeris am 10. März an der Leerink Global Healthcare Conference in Miami teilnehmen, wo ein informelles Gespräch für 8:40 Uhr ET angesetzt ist, gefolgt von der 27. Jahreskonferenz für Global Healthcare von Barclays in Miami am 11. März, die ausschließlich für 1x1-Meetings vorgesehen ist.
Das wachstumsorientierte Biopharmaunternehmen, das sich auf die Entwicklung und Vermarktung innovativer therapeutischer Produkte konzentriert, wird sein Führungsteam für persönliche Meetings bei allen drei Veranstaltungen zur Verfügung stellen. Interessierte Parteien können über die Investor-Relations-Website von Xeris auf die Informationen der Webcasts für die informellen Gespräche zugreifen.
- None.
- None.
-
Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual)
- 1x1 meetings and fireside chat February 12, 2025 at 1:20 pm ET
-
Leerink Global Healthcare Conference,
Miami, FL - 1x1 meetings and fireside chat on March 10, 2025 at 8:40 am ET
-
Barclays 27th Annual Global Healthcare Conference,
Miami, FL - 1x1 meetings only on March 11, 2025
Please check with each conference sponsor to arrange 1x1 meetings.
Webcast information for each fireside chat will be available at https://xerispharma.com/investor-relations.
About Xeris
Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Recorlev®, for the treatment of endogenous Cushing’s syndrome; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, as well as multiple early-stage programs leveraging Xeris’ technology platforms, XeriSol® and XeriJect®, for its partners.
Xeris Biopharma Holdings is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250205312553/en/
Investor Contact
Allison Wey
Senior Vice President, Investor Relations and Corporate Communications
awey@xerispharma.com
Source: Xeris Biopharma Holdings, Inc.
FAQ
When is Xeris Biopharma (XERS) presenting at the Oppenheimer Healthcare Conference in 2025?
What investor conferences will XERS attend in March 2025?
Where can investors access the webcast for Xeris' conference presentations?
Which upcoming XERS conference appearances include fireside chats?
